Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 5:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Acute Myeloid Leukemia With FLT3/ITD Mutation Clear all
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, FLT3 Tyrosine Kinase Domain Point Mutation, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
Decitabine, Laboratory Biomarker Analysis, Midostaurin
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
60 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Acute Myeloid Leukemia With FLT3/ITD Mutation
Interventions
Bone Marrow Transplantation, Sorafenib, Sorafenib Tosylate
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced May 21, 2026, 5:35 PM EDT
Active, not recruiting Phase 3 Interventional Results available
View directory record Official record
Conditions
Acute Myeloid Leukemia, Leukemia Cutis, Myeloid Neoplasm, Myeloid Sarcoma
Interventions
Asparaginase, Bortezomib, Cytarabine, Daunorubicin Hydrochloride, Etoposide, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride, Pharmacological Study, Quality-of-Life Assessment, Questionnaire Administration, Sorafenib Tosylate
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 29 Years
Enrollment
1,645 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
195
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 143 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
gilteritinib, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
46
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced May 21, 2026, 5:35 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
BMF-500
Drug
Lead sponsor
Biomea Fusion Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
14
States / cities
Phoenix, Arizona • Duarte, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Sorafenib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced May 21, 2026, 5:35 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Leukemia in Remission, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, Aplastic Anemia, B-Cell Non-Hodgkin Lymphoma, CD40 Ligand Deficiency, Chronic Granulomatous Disease, Chronic Leukemia in Remission, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Congenital Amegakaryocytic Thrombocytopenia, Congenital Neutropenia, Congenital Pure Red Cell Aplasia, Glanzmann Thrombasthenia, Immunodeficiency Syndrome, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Paroxysmal Nocturnal Hemoglobinuria, Plasma Cell Myeloma, Polycythemia Vera, Recurrent Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome, Severe Aplastic Anemia, Shwachman-Diamond Syndrome, Sickle Cell Disease, T-Cell Non-Hodgkin Lymphoma, Thalassemia, Waldenstrom Macroglobulinemia, Wiskott-Aldrich Syndrome
Interventions
Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Peripheral Blood Stem Cell Transplantation, Total-Body Irradiation
Drug · Other · Procedure + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
1 Year to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced May 21, 2026, 5:35 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Quizartinib, Fludarabine, Cytarabine, Intrathecal (IT) triple chemotherapy prophylaxis, Etoposide
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
1 Month to 21 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
11
States / cities
Loma Linda, California • San Francisco, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced May 21, 2026, 5:35 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Acute Biphenotypic Leukemia, Acute Erythroid Leukemia in Remission, Acute Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukaemia With Prior Myelodysplastic Syndrome, Acute Myeloid Leukemia in Remission, Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Inv(3)(Q21Q26.2); RPN1-EVI1, Acute Myeloid Leukemia With Multilineage Dysplasia, Acute Myeloid Leukemia With t(6;9), Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission, B Acute Lymphoblastic Leukemia With T(1;19)(Q23;P13.3); E2A-PBX1 (TCF3-PBX1), Ph+ ALL, Burkitt Lymphoma, Childhood Acute Lymphoblastic Leukemia in Complete Remission, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Myelodysplastic Syndrome, Recurrent Anaplastic Large Cell Lymphoma, Blasts Under 5 Percent of Bone Marrow Nucleated Cells, Recurrent Follicular Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, Secondary Acute Myeloid Leukemia, T Lymphoblastic Lymphoma, Hematopoietic Cell Transplant Recipient
Interventions
Cyclophosphamide, Filgrastim, Fludarabine Phosphate, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Total-Body Irradiation
Drug · Biological · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 22, 2023 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Acute Myeloid Leukemia, Leukemia
Interventions
Chemotherapy, Quizartinib, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
11
States / cities
Gainesville, Florida • Chicago, Illinois • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced May 21, 2026, 5:35 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With KMT2A Rearrangement, Acute Myeloid Leukemia With NPM1 Mutation, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Gilteritinib, Revumenib, Echocardiography Test, Multigated Acquisition Scan
Procedure · Drug
Lead sponsor
Uma Borate
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Chapel Hill, North Carolina • Columbus, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Leukemia
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, methotrexate, methylprednisolone, tacrolimus, laboratory biomarker analysis, pharmacological study, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation
Biological · Drug · Other + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
48
States / cities
Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 45 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced May 21, 2026, 5:35 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Acute Myeloid Leukemia, Leukemia
Interventions
Quizartinib High Dose, Quizartinib Low Dose
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
9
States / cities
Baltimore, Maryland • Worcester, Massachusetts • Buffalo, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced May 21, 2026, 5:35 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
CG-806
Drug
Lead sponsor
Aptose Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
10
States / cities
Duarte, California • Los Angeles, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Leukemia
Interventions
Azacytidine, Sorafenib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced May 21, 2026, 5:35 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Leukemia
Interventions
Quizartinib, Placebo, Chemotherapy
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 70 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
53
States / cities
Goodyear, Arizona • Phoenix, Arizona • Tucson, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM, Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214, Aplastic Anemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Follicular Lymphoma, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloid Leukemia, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Polycythemia Vera, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
Interventions
Fludarabine phosphate, Busulfan, Total-Body Irradiation, Therapeutic Allogeneic Lymphocytes, Cyclophosphamide, Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Mycophenolate Mofetil, Laboratory Biomarker Analysis
Drug · Radiation · Biological + 2 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
Not listed
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
sorafenib, vorinostat and bortezomib
Drug
Lead sponsor
Hamid Sayar
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation
Interventions
Gilteritinib, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
6
States / cities
Gainesville, Florida • Jacksonville, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
AC220
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
18
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Midostaurin, Standard of Care
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
18
States / cities
La Jolla, California • Los Angeles, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced May 21, 2026, 5:35 PM EDT
No Longer Available No phase listed Expanded access
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML) With, FLT3 Mutation, Internal Tandem Duplication (ITD) or Tyrosine Kinase Domain (TKD)
Interventions
Midostaurin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
44
States / cities
Phoenix, Arizona • Berkeley, California • Duarte, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
PLX3397
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
9
States / cities
San Francisco, California • Chicago, Illinois • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced May 21, 2026, 5:35 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Acute Myeloid Leukemia With FLT3/ITD Mutation
Interventions
Gilteritinib, Vyxeos
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced May 21, 2026, 5:35 PM EDT